ArticleSurgery in practice and science2026
The textbook outcome of pancreaticoduodenectomy for adenocarcinoma of the pancreas in a high-volume centre.
Article in Surgery in practice and science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic adenocarcinoma remains a leading cause of cancer-related mortality, with only 15-20% of patients eligible for resection at diagnosis. Pancreaticoduodenectomy (PD) is the standard surgical treatment, yet achieving optimal outcomes is challenging. Textbook Outcome (TO), a composite measure of quality, has emerged as a superior indicator of surgical success compared to individual parameters. This study evaluates TO in PD for pancreatic adenocarcinoma at a high-volume center and its impact on survival. Methods: This was a retrospective analysis conducted at a tertiary cancer center. TO was defined by negative resection margins, ≥12 lymph nodes retrieved, ICU stay <72 h, hospital stay ≤14 days, no readmission within 30 days, no major complications (Clavien-Dindo grade ≥3), and no postoperative pancreatic fistula grade B or C. Patients who underwent pancreaticoduodenectomy for adenocarcinoma pancreas were included. Patients with incomplete data for TO were excluded. Results: A total of 269 patients were included. Complete TO was achieved in 56.9% of patients. Most achieve outcome was negative margins (R0) in 94.8%, and ≥12 lymph nodes were retrieved in 92.6%. Least achieved outcome was hospital stays >14 days in 85%. Overall Survival in patients achieving TO vs those who did not achieved TO was 49 ± 1 month vs 40 ± 2 months respectively. ( Conclusion: Our tertiary cancer center demonstrated better TO rates compared to international published literature, reinforcing the importance of structured quality metrics in pancreatic surgery. TO serves as a robust predictor of long-term survival and should be integrated into surgical audits to enhance patient-centered care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.